TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16580587
Drug: Pistachio diet
Normalized name: Pistachio
DrugBank: Pistachio (DB10559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistachio diet (substituting pistachio nuts for 20% of daily caloric intake for 3 weeks)
Study: 10902094
Drug: Serotonin-reuptake inhibitors
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin-reuptake inhibitors
Study: 10902094
Drug: Buspirone, mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone, mood stabilizers, beta-blockers
Study: 9229615
Drug: Cordipin chronotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordipin chronotherapy (10 mg once a day based on chronosensitivity)
Study: 9229615
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with cordipin (10 mg 3 times a day)
Study: 2934557
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg adjuvant medroxyprogesterone 3 times a week for 1 year
Study: 28557043
Drug: Nurse-led psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led psychological intervention programme (seven weekly counselling sessions)
Study: 25550013
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood injection (2 ml of autologous venous blood mixed with 1 ml of 2% prilocaine hydrochloride)
Study: 25550013
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (1 ml of 40 mg methylprednisolone acetate mixed with 1 ml of 2% prilocaine hydrochloride)
Study: 11732218
Drug: Topical Beta-blockers
Normalized name: Beta-HC Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Beta-blockers and steroids
Study: 23614393
Drug: Lacosamide 200
Normalized name: lacosamide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide 200 mg twice daily on days 1-9 with a single 25 mg dose of warfarin coadministered on day 3
Study: 23614393
Drug: Warfarin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin alone (25 mg)
Study: 20429947
Drug: Online treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online treatment program for GAD, E‐couch
Study: 20429947
Drug: Sertraline (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (25-100 mg/day)
Study: 8601640
Drug: Bradykinin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin infusion (27 microgram over 100 min) during normoglycemic hyperinsulinemic conditions
Study: 8601640
Drug: Bradykinin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin infusion (27 microgram over 100 min) in the basal state
Study: 3879175
Drug: Suprofen syrup
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprofen syrup (5-7.5 mg/kg b.w., orally)
Study: 3879175
Drug: L PDP
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L PDP ear drops (1 drop, locally)
Study: 27749377
Drug: Case management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case management intervention (details on dosage and duration not specified)
Study: 27382934
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous hyoscine-N-butylbromide
Study: 27382934
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline solution (placebo)
Study: 17593071
Drug: 0.1 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mol/L hydrochloric acid infusion (150 mL at 15 mL/min for 10 min)
Study: 17593071
Drug: Pure water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure water infusion (150 mL)
Study: 11549532
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol dry powder 12 or 24 microg twice daily
Study: 11549532
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 40 microg four times daily
Study: 3415801
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg every 12 hours)
Study: 29297958
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied clobetasol propionate 0.05% (mixed with 4% hydroxyethyl cellulose gel)
Study: 29297958
Drug: 4% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% hydroxyethyl cellulose gel alone (placebo)
Study: 26924818
Drug: Axomadol (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axomadol (doses ranging from 66 mg to 225 mg)
Study: 26285662
Drug: Acute simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute simvastatin treatment
Study: 23659755
Drug: Sotrastaurin 300
Normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin 300 mg
Study: 23659755
Drug: Sotrastaurin 200
Normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin 200 mg
Study: 7559885
Drug: Intravenous GHRP-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GHRP-2
Study: 7559885
Drug: Intranasal GHRP-2
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal GHRP-2 (5-20 micrograms/kg per dose)
Study: 7559885
Drug: GHRH +
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH + GHRP-2 (administered simultaneously)
Study: 7559885
Drug: Conventional agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional agents (arginine, L-dopa/exercise, insulin)
Study: 7197960
Drug: Quinidine (492
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (492 mg quinidine-base as quinidine-bisulfate)
Study: 7448345
Drug: Quinidine formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine formulation 1
Study: 7448345
Drug: Quinidine formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine formulation 2
Study: 28334675
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) (n=20)
Study: 25987642
Drug: S-ketamine (0.006
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (0.006 mg/Kg)
Study: 22948968
Drug: Doxorubicin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 30 mg/m²
Study: 22948968
Drug: Daunorubicin 30
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin 30 mg/m²
Study: 22948968
Drug: Daunorubicin 40
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin 40 mg/m²
Study: 7836510
Drug: Oestrogen-progestin add-back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestrogen-progestin add-back therapy (0.75 mg oestropipate daily + 0.7 mg norethindrone on days 1-14 each month)
Study: 7836510
Drug: Progestin add-back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progestin add-back therapy (10 mg norethindrone daily)
Study: 7836510
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot (3.75 mg every 4 weeks for 2 years)
Study: 2972550
Drug: Co-dergocrine (DA2-agonist)
Normalized name: co-dergocrine mesylate
DrugBank: Ergoloid mesylate (DB01049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-dergocrine (DA2-agonist)
Study: 31669193
Drug: AS37-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS37-adjuvanted vaccine (TLR7a dose 12.5, 25, 50, 100 μg)
Study: 31669193
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (licensed MenC conjugate alum-adjuvanted vaccine)
Study: 31669193
Drug: AS37-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS37-adjuvanted vaccine (TLR7a 100 μg)
Study: 25833032
Drug: AmED 500
Normalized name: Encora AM Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmED 500 ml energy drink (ED)
Study: 25833032
Drug: AmED 750
Normalized name: Encora AM Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmED 750 ml energy drink (ED)
Study: 23499420
Drug: Slow-tempo music
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-tempo music listening (two 1-hour daily periods)
Study: 19680456
Drug: Valacyclovir 1
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1 g daily
Study: 14961155
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of antithrombin III (6 vials: 3000 units) once daily for 5 days or until delivery
Study: 14961155
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of antithrombin III (sufficient to maintain at least 80% activity)
Study: 14961155
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of antithrombin III
Study: 14961155
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (high doses and standard doses)
Study: 12501151
Drug: Sucralfate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (60 mg/kg/d in 4 doses via nasogastric tube)
Study: 12501151
Drug: Ranitidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (2 mg/kg/d intravenously in 4 doses)
Study: 12501151
Drug: Omeprazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (1 mg/kg/d intravenously in 2 doses)
Study: 7619035
Drug: Inhalation rewarming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation rewarming with the Heat Treat
Study: 2096602
Drug: AT877 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT877 20 mg
Study: 2096602
Drug: AT877 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT877 40 mg
Study: 2096602
Drug: AT877 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT877 60 mg
Study: 2096602
Drug: AT877 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT877 90 mg
Study: 2096602
Drug: AT877 120-180
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT877 120-180 mg
Study: 24108314
Drug: Cinacalcet (30-180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (30-180 mg daily)
Study: 21723949
Drug: Low-dose S-ketamine
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose S-ketamine (0.1mg/kg bolus for 5min, continuous infusion of 0.015625mg/kg/min reduced by 10% every ten minutes)
Study: 16442905
Drug: No coronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No coronary artery disease, second or greater episode of AF, left ventricular ejection fraction < 0.50, and mitral valve thickening (in patients not taking antiarrhythmic drug therapy)
Study: 16442905
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial diameter > 4.5 cm and mitral valve thickening (in patients taking antiarrhythmic medication)
Study: 8323383
Drug: Hydroxychloroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (400 mg daily for 12 months)
Study: 3547300
Drug: Tocopherol (adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocopherol (adjusted to plasma levels of 3 to 3.5 mg/dL)
Study: 23067920
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily aspirin (150 mg in the morning)
Study: 23067920
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily aspirin (75 mg in the morning and 75 mg in the evening)
Study: 20052721
Drug: 3-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hour infusion of paclitaxel at a dose of 250 mg/m² iv every 21 days
Study: 20052721
Drug: 96-hour infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 96-hour infusion of paclitaxel at a dose of 140 mg/m² iv every 21 days
Study: 9725480
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 50% drug in core and 180 mg HPMC in coat
Study: 9725480
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 67% drug in core and 180 mg HPMC in coat
Study: 9725480
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 80% drug in core and 180 mg HPMC in coat
Study: 9725480
Drug: Tablets with
Normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with whole dose in core
Study: 9725480
Drug: Tablets with
Normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with doubled amount of HPMC in coat
Study: 8040738
Drug: Intranasal sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sedation (INS) with 0.5% midazolam
Study: 8040738
Drug: Bolus intravenous
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous sedation (BIVS) with 1 mg midazolam as needed
Study: 28987658
Drug: Adipose-derived stromal
Normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose-derived stromal vascular fraction injection
Study: 21487089
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (pravastatin 40 mg)
Study: 12510818
Drug: Moderate-impact exercise
Normalized name: IMPACT
DrugBank: Topramezone (DB14826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-impact exercise with calcium supplementation (434 ± 19 mg/day)
Study: 12510818
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (434 ± 19 mg/day) without exercise
Study: 3780897
Drug: FET with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FET with PD during treatment sessions
Study: 29315686
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with l-carnitine, acetyl-l-carnitine and other micronutrients for 6 months
Study: 20018320
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injection at a concentration of 10 U/ml to 3 locations around the ureteral orifice
Study: 15259473
Drug: Artesunate (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (8 mg/kg for 3 days)
Study: 15259473
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg for 3 days)
Study: 8560661
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (laser therapy and TURP)
Study: 31394994
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) only
Study: 19680234
Drug: Extra high-catechin
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extra high-catechin GT3 (886 mg catechins, 198 mg caffeine/day)
Study: 19680234
Drug: High-catechin GT2
Normalized name: (+)-catechin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-catechin GT2 (468 mg catechins, 126 mg caffeine/day)
Study: 19680234
Drug: High-catechin GT1
Normalized name: (+)-catechin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-catechin GT1 (458 mg catechins, 104 mg caffeine/day)
Study: 19680234
Drug: Control drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drink (30 mg catechins, 10 mg caffeine/day)
Study: 18931242
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine followed by 0.5% bupivacaine (L/B)
Study: 17433897
Drug: Risk factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factors for venous thrombosis including age, surgery, hospitalization, immobility, trauma, pregnancy, hormone use, cancer, obesity, and hypercoagulation disorders.
Study: 10928462
Drug: Antibody against
Normalized name: recombinant human IgG4 monoclonal antibody against FGF19
DrugBank: HH-009 (DB18727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody against factor XI
Study: 9496216
Drug: i.v. thiopentone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. thiopentone combined with i.m. lignocaine (3.0 mg kg‐1)
Study: 9496216
Drug: i.v. thiopentone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. thiopentone combined with i.m. bupivacaine (1.0 mg kg‐1)
Study: 3529971
Drug: timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol 0.5% plus dipivefrin 0.1% twice daily given ten minutes apart
Study: 3529971
Drug: timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol 0.5% plus dipivefrin 0.1% given twice daily four hours apart
Study: 23591634
Drug: High-sensitivity C-reactive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity C-reactive protein, interleukin 6, receptor activator of nuclear factor κB ligand
Study: 21673183
Drug: PE-formula (3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE-formula (3.1 ± 0.3 g protein/kg/24 h, 119 ± 25 kcal/kg/24 h)
Study: 21673183
Drug: S-formula (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-formula (1.7 ± 0.2 g protein/kg/24 h, 84 ± 15 kcal/kg/24 h)
Study: 19922880
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg (1 tablet) alone
Study: 19922880
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg (1 tablet) plus probucol 500 mg (2 tablets)
Study: 19922880
Drug: Probucol 250
Normalized name: probucol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 250 mg (1 tablet) alone
Study: 19922880
Drug: Probucol 250
Normalized name: probucol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 250 mg (1 tablet) plus cilostazol 100 mg (1 tablet)
Study: 17070169
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus warfarin
Study: 17070169
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ximelagatran
Study: 8452163
Drug: Low-dose fleroxacin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fleroxacin (200 mg once daily)
Study: 8452163
Drug: High-dose fleroxacin
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fleroxacin (400 mg once daily)
Study: 26163338
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherry concentrate (30 mL)
Study: 26163338
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherry concentrate (60 mL)
Study: 26163338
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PCA and VA
Study: 25134285
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 ug, 6 and 12 hours prior to surgery)
Study: 25134285
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol (400 ug, 6 and 12 hours prior to surgery)
Study: 22915652
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg on day 3 and 80 mg per day on days 4 through 7
Study: 9514186
Drug: MDL 100,240
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 100,240 (doses: 1.56 mg, 6.25 mg, 25 mg, 3.13 mg, 12.5 mg, 50 mg)
Study: 9514186
Drug: MDL 100,240
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 100,240 (doses: 3.125 mg, 25 mg, 50 mg)
Study: 31843995
Drug: SUL-DUR (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUL-DUR (1 g/1 g intravenously every 6 hours for 7 days)
Study: 31843995
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous every 6 hours for 7 days)
Study: 31843995
Drug: SUL-DUR with
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUL-DUR with IMI background therapy
Study: 16354458
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (ccHRT; Indivina, Orion Pharma, Finland)
Study: 10644486
Drug: Rectal pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal pacing with 5-mA amplitude and 200-ms pulse width
Study: 10644486
Drug: Rectal pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal pacing in study group
Study: 6398158
Drug: Clozic (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozic (100 mg/day)
Study: 6398158
Drug: Clozic (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozic (300 mg/day)
Study: 6398158
Drug: D-penicillamine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (500 mg/day)
Study: 6398158
Drug: Aspirin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (up to 3.6 g/day)
Study: 30350779
Drug: Community-wide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide treatment (CWT) for 4 years
Study: 30350779
Drug: School-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based treatment (SBT) for 2 years followed by 2 years without treatment (holiday)
Study: 30350779
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of SBT combined with 2 years of treatment holiday
Study: 26761518
Drug: Low-dose IL-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose IL-12 (50 μg) with HIV MAG pDNA by IM-EP